Infectious diseases company Pneumagen (Holdings) Ltd on Wednesday announced GBP4m in investment led by Thairm Bio, Scottish Investment Bank (SIB) to progress the company's lead candidate, Neumifil into a clinical trial for COVID-19.
Neumifil is a first-in-class Carbohydrate Binding Modules (mCBMs), generated using Pneumagen's proprietary GlycoTarge platform. It is being developed for the universal treatment of respiratory tract infections (RTIs) caused by Influenza Virus and Respiratory Syncytial Virus and now coronaviruses including SARS-CoV-2, the cause of COVID-19.
The investment follows exciting data from Pneumagen's pre-clinical studies in COVID-19 using plaque reduction assays. The testing conducted at Public Health England's (PHE) Porton facility and from the University of Glasgow's MRC Centre for Virus Research, demonstrated efficacy in inhibiting SARS-CoV-2 infection.
(USD1=GBP0.82)
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial